Beyond antibodies: New affinity reagents to unlock the proteome
暂无分享,去创建一个
Larry Gold | L. Gold | B. Lollo | Fintan Steele | Bridget Lollo | F. Steele
[1] Tracy R. Keeney,et al. Aptamer-based multiplexed proteomic technology for biomarker discovery , 2010, Nature Precedings.
[2] S. Yokoyama,et al. Anti-(Raf-1) RNA aptamers that inhibit Ras-induced Raf-1 activation. , 2002, European journal of biochemistry.
[3] Maria P. Pavlou,et al. The long journey of cancer biomarkers from the bench to the clinic. , 2013, Clinical chemistry.
[4] S. Missailidis,et al. Aptamers as inhibitors of target proteins , 2009, Expert opinion on therapeutic patents.
[5] H. Hoogenboom,et al. Selecting and screening recombinant antibody libraries , 2005, Nature Biotechnology.
[6] B. Haab. Methods and applications of antibody microarrays in cancer research , 2003, Proteomics.
[7] Stephen A. Williams,et al. Unlocking Biomarker Discovery: Large Scale Application of Aptamer Proteomic Technology for Early Detection of Lung Cancer , 2010, PloS one.
[8] Rachel Ostroff,et al. Life's simple measures: unlocking the proteome. , 2012, Journal of molecular biology.
[9] N. Janjić,et al. High-affinity RNA ligands to basic fibroblast growth factor inhibit receptor binding. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[10] Rachel Ostroff,et al. The stability of the circulating human proteome to variations in sample collection and handling procedures measured with an aptamer-based proteomics array. , 2010, Journal of proteomics.
[11] John McCafferty,et al. Beyond natural antibodies: the power of in vitro display technologies , 2011, Nature Biotechnology.
[12] S. Berson,et al. Assay of Plasma Insulin in Human Subjects by Immunological Methods , 1959, Nature.
[13] N. Janjić,et al. Detection of Clostridium difficile toxins A, B and binary toxin with slow off-rate modified aptamers. , 2013, Diagnostic microbiology and infectious disease.
[14] C. Milstein,et al. Continuous cultures of fused cells secreting antibody of predefined specificity , 1975, Nature.
[15] Pei Wang,et al. The interface between biomarker discovery and clinical validation: The tar pit of the protein biomarker pipeline , 2008, Proteomics. Clinical applications.
[16] Dan Schneider,et al. Expanding the chemistry of DNA for in vitro selection. , 2010, Journal of the American Chemical Society.
[17] J. Foote,et al. Kinetic and affinity limits on antibodies produced during immune responses. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[18] L. Gold,et al. Bent pseudoknots and novel RNA inhibitors of type 1 human immunodeficiency virus (HIV-1) reverse transcriptase. , 1996, Journal of molecular biology.
[19] Vivien Marx,et al. Finding the right antibody for the job , 2013, Nature Methods.
[20] L. Gold,et al. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. , 1990, Science.
[21] Sheri K. Wilcox,et al. Protein Signature of Lung Cancer Tissues , 2012, PloS one.
[22] Sheri K. Wilcox,et al. Aptamers and the RNA world, past and present. , 2012, Cold Spring Harbor perspectives in biology.
[23] M Yarus,et al. Diversity of oligonucleotide functions. , 1995, Annual review of biochemistry.
[24] J. Hopfield. Kinetic proofreading: a new mechanism for reducing errors in biosynthetic processes requiring high specificity. , 1974, Proceedings of the National Academy of Sciences of the United States of America.
[25] C. Barbas. Synthetic human antibodies , 1995, Nature Medicine.
[26] Tracy R. Keeney,et al. Age-dependent changes in the cerebrospinal fluid proteome by slow off-rate modified aptamer array. , 2012, The American journal of pathology.
[27] A. Pardi,et al. High-resolution molecular discrimination by RNA. , 1994, Science.
[28] J. Ninio. Kinetic amplification of enzyme discrimination. , 1975, Biochimie.
[29] P. T. Jones,et al. Isolation of high affinity human antibodies directly from large synthetic repertoires. , 1994, The EMBO journal.
[30] George G Klee,et al. Antibody-based protein multiplex platforms: technical and operational challenges. , 2010, Clinical chemistry.
[31] J. Frystyk,et al. The current status of IGF-I assays--a 2009 update. , 2010, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.
[32] Jonathan D. Vaught,et al. Measurement of Cetuximab and Panitumumab-Unbound Serum EGFR Extracellular Domain Using an Assay Based on Slow Off-Rate Modified Aptamer (SOMAmer) Reagents , 2013, PloS one.
[33] Gary Walsh,et al. Post-translational modifications in the context of therapeutic proteins , 2006, Nature Biotechnology.
[34] A. Varki,et al. DNA aptamers block L-selectin function in vivo. Inhibition of human lymphocyte trafficking in SCID mice. , 1996, The Journal of clinical investigation.
[35] D. Bunka,et al. Aptamers come of age – at last , 2006, Nature Reviews Microbiology.
[36] R Thorpe,et al. Immunoassays for detecting cytokines: what are they really measuring? , 1995, Journal of immunological methods.
[37] J. Latham,et al. The application of a modified nucleotide in aptamer selection: novel thrombin aptamers containing 5-(1-pentynyl)-2'-deoxyuridine. , 1994, Nucleic acids research.
[38] G. Winter,et al. Phage antibodies: filamentous phage displaying antibody variable domains , 1990, Nature.
[39] Daniel O'Connell,et al. Unique motifs and hydrophobic interactions shape the binding of modified DNA ligands to protein targets , 2012, Proceedings of the National Academy of Sciences.
[40] Harald Schumny,et al. Next generation , 2005, Comput. Stand. Interfaces.
[41] Sheri K. Wilcox,et al. Rapid Histochemistry Using Slow Off-rate Modified Aptamers With Anionic Competition , 2011, Applied immunohistochemistry & molecular morphology : AIMM.
[42] C. Barbas,et al. Assembly of combinatorial antibody libraries on phage surfaces: the gene III site. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[43] S. Jayasena. Aptamers: an emerging class of molecules that rival antibodies in diagnostics. , 1999, Clinical chemistry.
[44] K. Horii,et al. Quantitative and sensitive protein detection strategies based on aptamers , 2012, Proteomics. Clinical applications.
[45] Martina Rimmele,et al. Nucleic Acid Aptamers as Tools and Drugs: Recent Developments , 2003, Chembiochem : a European journal of chemical biology.
[46] Tracy R. Keeney,et al. From SOMAmer-Based Biomarker Discovery to Diagnostic and Clinical Applications: A SOMAmer-Based, Streamlined Multiplex Proteomic Assay , 2011, PloS one.
[47] R. Stoltenburg,et al. SELEX--a (r)evolutionary method to generate high-affinity nucleic acid ligands. , 2007, Biomolecular engineering.
[48] N. Janjić,et al. Inhibition of receptor binding by high-affinity RNA ligands to vascular endothelial growth factor. , 1994, Biochemistry.
[49] J. Szostak,et al. In vitro selection of RNA molecules that bind specific ligands , 1990, Nature.
[50] B. Mumey,et al. Antigen-antibody interface properties: composition, residue interactions, and features of 53 non-redundant structures. , 2012, Biochimica et biophysica acta.
[51] Maria C. DeRosa,et al. Challenges and Opportunities for Small Molecule Aptamer Development , 2012, Journal of nucleic acids.
[52] S. Ringquist,et al. Anti-L-selectin oligonucleotide ligands recognize CD62L-positive leukocytes: binding affinity and specificity of univalent and bivalent ligands. , 1998, Cytometry.
[53] Stephen A. Williams,et al. Early Detection of Malignant Pleural Mesothelioma in Asbestos-Exposed Individuals with a Noninvasive Proteomics-Based Surveillance Tool , 2012, PloS one.
[54] Richard T. Lee,et al. Growth Differentiation Factor 11 Is a Circulating Factor that Reverses Age-Related Cardiac Hypertrophy , 2013, Cell.
[55] Yi Xiao,et al. Probing the Limits of Aptamer Affinity with a Microfluidic SELEX Platform , 2011, PloS one.